Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.
Hoeper MM, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, Wirtz H, Helmersen DS, Tsangaris I, Barberà JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, Šimková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Ghofrani HA; Collaborators list. Hoeper MM, et al. Among authors: langleben d. Respir Med. 2021 Feb;177:106241. doi: 10.1016/j.rmed.2020.106241. Epub 2020 Dec 3. Respir Med. 2021. PMID: 33422952 Free article.
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.
Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Solèr M. Langleben D, et al. Am Heart J. 2002 May;143(5):E4. doi: 10.1067/mhj.2002.121806. Am Heart J. 2002. PMID: 12040360 Clinical Trial.
Updated clinical classification of pulmonary hypertension.
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Simonneau G, et al. Among authors: langleben d. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54. doi: 10.1016/j.jacc.2009.04.012. J Am Coll Cardiol. 2009. PMID: 19555858 Free article. Review.
High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.
Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, Eisenberg MJ, Joyal D, Hudson M, Boutet K, Serban A, Masetto A, Baron M. Fox BD, et al. Among authors: langleben d. Eur Respir J. 2013 Oct;42(4):1083-91. doi: 10.1183/09031936.00091212. Epub 2012 Dec 20. Eur Respir J. 2013. PMID: 23258775 Free article.
Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group. Ghofrani HA, et al. Among authors: langleben d. N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655. N Engl J Med. 2013. PMID: 23883378 Free article. Clinical Trial.
Definitions and diagnosis of pulmonary hypertension.
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Hoeper MM, et al. Among authors: langleben d. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032. J Am Coll Cardiol. 2013. PMID: 24355641 Free article. Review.
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, Subías PE, Galiè N, Pfister T, Lemarié JC, Simonneau G. Sitbon O, et al. Among authors: langleben d. Am Heart J. 2014 Feb;167(2):210-7. doi: 10.1016/j.ahj.2013.08.007. Epub 2013 Oct 3. Am Heart J. 2014. PMID: 24439982 Free article. Clinical Trial.
218 results